Amberstone Biosciences

About

Amberstone Biosciences is a biotechnology company based in Irvine, California, founded in 2018. The company specializes in developing tumor microenvironment-activated immunotherapies aimed at treating solid cancers. Led by CEO Guikai George Wu, Amberstone focuses on creating targeted active immunotherapeutics that address the limitations of traditional cancer treatments. The company's innovative T-MATE™ (Tumor Microenvironment Activated Therapeutics) platform utilizes the acidic environment of tumors to selectively activate therapeutic molecules, minimizing effects on healthy tissues. This approach allows for a broader therapeutic window and revisits treatment options that may have been too toxic for conventional development. Amberstone's drug pipeline includes bispecific T-cell engagers, bifunctional proteins, and fusion proteins, all currently in preclinical or discovery stages, targeting solid tumors and autoimmune diseases. Amberstone has successfully raised $12 million in Series A funding to further develop its therapeutic solutions and is exploring partnerships and collaborations to enhance its growth in the healthcare sector.